Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Fulacimstat (Primary)
- Indications Kidney disorders; Left ventricular dysfunction; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bayer
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.
- 26 Jan 2018 Planned End Date changed from 30 Oct 2018 to 21 Nov 2018.
- 26 Jan 2018 Planned primary completion date changed from 28 Sep 2018 to 19 Oct 2018.